- Home
- EVO vs IMSR Comparison
EVO vs IMSR Comparison
Compare EVO & IMSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVO
- IMSR
- Stock Information
- Founded
- EVO 1993
- IMSR 2013
- Country
- EVO Germany
- IMSR United States
- Employees
- EVO N/A
- IMSR N/A
- Industry
- EVO Biotechnology: Pharmaceutical Preparations
- IMSR
- Sector
- EVO Health Care
- IMSR
- Exchange
- EVO Nasdaq
- IMSR Nasdaq
- Market Cap
- EVO 1.4B
- IMSR 1.7B
- IPO Year
- EVO 2021
- IMSR N/A
- Fundamental
- Price
- EVO $3.31
- IMSR $13.72
- Analyst Decision
- EVO Strong Buy
- IMSR
- Analyst Count
- EVO 1
- IMSR 0
- Target Price
- EVO $7.00
- IMSR N/A
- AVG Volume (30 Days)
- EVO 54.5K
- IMSR 2.0M
- Earning Date
- EVO 11-05-2025
- IMSR 01-01-0001
- Dividend Yield
- EVO N/A
- IMSR N/A
- EPS Growth
- EVO N/A
- IMSR N/A
- EPS
- EVO N/A
- IMSR N/A
- Revenue
- EVO $887,396,457.00
- IMSR $123,320.00
- Revenue This Year
- EVO N/A
- IMSR N/A
- Revenue Next Year
- EVO $10.78
- IMSR N/A
- P/E Ratio
- EVO N/A
- IMSR N/A
- Revenue Growth
- EVO N/A
- IMSR 1234.25
- 52 Week Low
- EVO $2.84
- IMSR $13.55
- 52 Week High
- EVO $5.64
- IMSR $21.00
- Technical
- Relative Strength Index (RSI)
- EVO 28.61
- IMSR N/A
- Support Level
- EVO $3.30
- IMSR N/A
- Resistance Level
- EVO $4.09
- IMSR N/A
- Average True Range (ATR)
- EVO 0.09
- IMSR 0.00
- MACD
- EVO -0.08
- IMSR 0.00
- Stochastic Oscillator
- EVO 2.06
- IMSR 0.00
About EVO Evotec SE
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.